Noninvasive Nasopharyngeal Proteomics Identify Coagulation Abnormalities in SARS-CoV-2

ABSTRACT: Vaccines/drugs that could utilize the mucosal immune system to produce antibodies in the nose should help stop the coronavirus at the point of entry. Therefore, Identification of biomarkers in nasal microenvironment associated with viral clearance, vaccine implementation, and easily measurable correlates of protection, can allow monitoring of infection-induced immunity and facilitate novel drug/vaccine development. Our study proposes to use mass spectrometry-based proteomics to reflect the host response to COVID-19 infection in the nasopharyngeal environment and to identify any new biomarkers that can be used for designing non-invasive prognostic tools and treatments at the point of entry of the virus.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Nasal Cavity, Epithelial Cell

DISEASE(S): Covid-19

SUBMITTER: Wanying Cao  

LAB HEAD: Lina Abi Mosleh

PROVIDER: PXD029143 | Pride | 2022-07-21

REPOSITORIES: Pride